20:42:27 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-11-15 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-05-17 Ordinarie utdelning CLS B 0.00 SEK
2024-04-12 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-06-29 Årsstämma 2023
2023-06-22 Ordinarie utdelning CLS B 0.00 SEK
2023-06-08 Extra Bolagsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-22 Extra Bolagsstämma 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-29 Ordinarie utdelning CLS B 0.00 SEK
2022-06-28 Årsstämma 2022
2022-05-19 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-29 Ordinarie utdelning CLS B 0.00 SEK
2021-06-28 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-31 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Ordinarie utdelning CLS B 0.00 SEK
2020-06-11 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-12 Ordinarie utdelning CLS B 0.00 SEK
2019-05-17 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-03-18 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-06-20 Årsstämma 2018
2018-06-14 Ordinarie utdelning CLS B 0.00 SEK
2018-05-24 Kvartalsrapport 2018-Q1
2018-05-18 Extra Bolagsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-07-17 Kvartalsrapport 2017-Q2
2017-06-28 Ordinarie utdelning CLS B 0.00 SEK
2017-06-27 Årsstämma 2017
2017-05-18 Kvartalsrapport 2017-Q1
2017-01-31 Bokslutskommuniké 2016
2017-01-20 Extra Bolagsstämma 2017
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-06-16 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-21 Bokslutskommuniké 2015
2015-11-19 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-06-12 Ordinarie utdelning CLS B 0.00 SEK
2015-06-11 Årsstämma 2015
2015-05-21 Kvartalsrapport 2015-Q1
2015-02-23 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-06-18 Ordinarie utdelning CLS B 0.00 SEK
2014-06-17 Årsstämma 2014
2014-05-22 Kvartalsrapport 2014-Q1
2014-02-24 Bokslutskommuniké 2013
2013-11-22 Kvartalsrapport 2013-Q3
2013-09-19 Extra Bolagsstämma 2013
2013-08-20 Kvartalsrapport 2013-Q2
2013-06-10 Ordinarie utdelning CLS B 0.00 SEK
2013-06-07 Årsstämma 2013
2013-05-24 Kvartalsrapport 2013-Q1
2013-02-25 Bokslutskommuniké 2012
2012-11-23 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-06-08 Ordinarie utdelning CLS B 0.00 SEK
2012-06-07 Årsstämma 2012
2012-04-20 Kvartalsrapport 2012-Q1
2012-01-09 Bokslutskommuniké 2011
2012-01-04 Extra Bolagsstämma 2012
2011-11-21 Kvartalsrapport 2011-Q3
2011-09-26 Kapitalmarknadsdag 2010
2011-08-22 Kvartalsrapport 2011-Q2
2011-06-10 Årsstämma 2011
2011-05-20 Kvartalsrapport 2011-Q1
2011-02-24 Bokslutskommuniké 2010
2010-11-24 Kvartalsrapport 2010-Q3
2010-08-25 Kvartalsrapport 2010-Q2
2010-05-28 Ordinarie utdelning CLS B 0.00 SEK
2010-05-26 Kvartalsrapport 2010-Q1
2010-02-26 Bokslutskommuniké 2009
2009-11-30 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Clinical Laserthermia Systems är verksamt inom medicinteknik. Bolagets vision är att utveckla och effektivisera behandlingen av solida cancertumörer, där bolaget är försäljare av sterila patientkit. Produkterna används i diverse cancerbehandlingar som vid behandling av malignt melanom, samt cancer i lungor, lever och bukspottkörtel. Bolaget grundades 2006 och har sitt huvudkontor i Lund.
2021-11-18 13:00:00

IRVINE, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS), developer of high precision, image-guided focal laser ablation (FLA) systems, today announced the company is once again releasing its complete range of TRANBERG sterile disposable products into the US market via its subsidiary CLS Americas Inc.

As a result of the intensive work of recent months to develop a new solution for sterilizing the company's disposable products, CLS is now releasing its complete range of TRANBERG® sterile disposable products into the US market through its subsidiary CLS Americas Inc. In April 2021, the company recalled all its sterile disposable products as a result of the company's previous supplier of these services being deprived of its certificate due to poor quality in its processes.

“It is with great satisfaction that I can now state that we again have sterile disposable products on the market. This has been achieved after intensive work landing a new supplier solution for our sterilization
that includes the German sterilization company Rose GmbH. In a next step, we will also release the complete range of our sterile disposable products for the European market. We expect to do so in the coming weeks,” says Dan Mogren, acting CEO of CLS.

Release and resumption of deliveries of sterile disposable products in Europe will take place after final approval by CLS's notified body, TüV Süd.

A new solution for sterilization of the company's disposable products also includes a build-up of redundancy to help ensure access to a validated sterilization process and capacity at more than one supplier. Such a solution provides the necessary flexibility and prevents future interruptions in the company's product delivery to the market.

CLS develops and sells TRANBERG® products for minimally invasive, high precision, image-guided laser ablation. In the EU, the products are approved for the treatment of soft tissue and malignant tumor disease. CLS initially focuses here on the treatment of malignant tumor disease in the prostate in the early stages, treatment of pancreatic cancer, and treatment in the brain of malignant tumor disease and drug-resistant epilepsy.

In the US, CLS's product portfolio has a market approval for soft tissue ablation and is sold mainly for image-guided, minimally invasive treatment in the prostate of malignant tumor disease in the early stage. Image-guided treatment means that the doctor uses magnetic resonance (MR) or ultrasound (US) image guidance during the treatment to identify the treatment area, determine the placement of instruments, and to monitor the ablation procedure with high precision and accuracy.

About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy System, including sterile disposables, for minimally invasive treatment of soft tissue such as cancer tumours and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.  For more information about CLS, please visit the Company's website: www.clinicallaser.se.

This press release has been translated and adapted from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

This information is such that CLS AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on November 17, 2021 at 13:00 PM CET.